Drugs in R&D · 2017 · 10 citations · 16 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyRenal PathophysiologyRenal PharmacotherapyChronic Kidney DiseaseDiabetic NephropathyDiuretic TherapyRenal DiseaseRenal Function TestsRenal PharmacologyGlomerular Filtration AssessmentGlomerular Filtration Rate AssessmentGlomerular Filtration Rate ComparisonGlomerular Filtration Rate MeasurementKidney Function MonitoringNifedipine TherapyRenal Function EvaluationSerum Creatinine Assessment
BACKGROUND: We conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension. METHODS: Using a clinical database, we identified new users of five CCBs, i.e. amlodipine (L-type, n = 693), nifedipine (L-type, n = 189), azelnidipine (L/T-type, n = 91), benidipine (L/N/T-type, n = 183), and cilnidipine (L/N-type, n = 61). We used a multivariable regression model to evaluate and compare the effects of these drugs on eGFR and serum creatinine, up to 12 months after initiation of study drug administration. RESULTS: There was no significant association between treatment duration and both eGFR and serum creatinine level with all CCB types. In addition, there was no significant difference in mean change in eGFR among the five CCBs, with any treatment duration. CONCLUSIONS: Our findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on renal function parameters and may be safely used in hypertensive patients with diabetes.
16
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo, Enyu Imai, Masaru Horio et al. · American Journal of Kidney Diseases · 2009 · 6.4K citations